drugset / Trial / NCT07074977
Proof of Concept Study to Assess the Pharmacokinetics/Pharmacodynamics of Nemolizumab in Adults With Chronic Pruritus of Unknown Origin (CPUO)
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The primary objective of this study is to assess the PK/PD relationship of nemolizumab in adult participants aged 18 years or above with chronic pruritus of unknown origin (CPUO) during a 16-week treatment period.
Timeline
- Start
- 2025-10-20
- Primary completion
- 2026-09
- Completion
- 2027-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nemolizumab | Monoclonal antibody | 30 mg | Subcutaneous |
| Subject | Nemolizumab | Monoclonal antibody | 60 mg | Subcutaneous |
Indications
No indication recorded.